Vitamin D3 for Life

Live Enlightened

Physiology

Hepatic CYP2R1 and Vitamin D Conversion: Study Summary

Previous related pageHepatic CYP2R1 and Vitamin D Conversion: Full StudyNext related pageHepatic CYP2R1 and Vitamin D Conversion: Full Study
Study at a glance

How does the liver start converting vitamin D?

This page brings together studies of CYP2R1, an enzyme that helps change vitamin D into 25-hydroxyvitamin D. This is the form measured in most vitamin D blood tests. Making the main active vitamin D hormone requires a separate, later step. The studies ask whether the first conversion can change with conditions in the body.

What did studies of the vitamin D conversion enzyme find?

Rare inherited changes in CYP2R1 were linked to rickets and reduced conversion. A report of 27 people from nine affected families supports its importance, but cannot show how common these problems are. Removing the gene in mice greatly reduced conversion without stopping it completely. High-fat feeding also reduced conversion in liver samples from female mice. These findings do not directly show what happens in human obesity.

Did the human and mouse findings show the same changes?

One human study sampled fat from four women before and after weight-loss surgery. It did not measure recovery of liver conversion. A human-cell model showed less conversion after fatty-acid exposure, but a separate patient liver analysis did not show reduced CYP2R1 production. In another experiment, diabetic mice had lower activity of the CYP2R1 gene but greater overall vitamin D conversion. Gene activity, enzyme amounts and conversion are different measurements.

Can a low vitamin D result identify a liver conversion problem?

CYP2R1 matters, and experimental studies show that conversion can respond to conditions in the body. These studies give less direct evidence about the human liver in ordinary obesity. A low vitamin D blood result alone cannot identify a conversion problem or separate it from low supply and other causes. The evidence does not provide a personal diagnosis, treatment or supplement dose.

Read the full article below ↓

CYP2R1 is an enzyme involved in making 25-hydroxyvitamin D, or 25(OH)D, the metabolite measured in most vitamin D blood tests. The evidence shows that conversion can be regulated, while also showing why a low blood result cannot identify one faulty step. For the detailed evidence and methods, see Hepatic CYP2R1 and Vitamin D Conversion: Full Study.

What question does this evidence answer?

The question is whether vitamin D conversion is simply an automatic response to supply, or whether the conversion machinery itself can change. This belongs within Vitamin D and Liver Function. It is different from asking whether supplementation improves a disease or what dose a person needs.

The first conversion produces 25(OH)D. A later, separate conversion produces calcitriol, the principal active hormone. The distinction is explained in Vitamin D Activation. A study must identify which step and which molecule it measured before its findings can be interpreted.

What did the studies find?

Human genetic research by Cheng and colleagues connected a rare CYP2R1 mutation with rickets and impaired vitamin D3 conversion in laboratory cells. It establishes biological importance, not the frequency of that mechanism in ordinary low vitamin D results.

Bakhamis and colleagues subsequently described 27 affected members of nine families. This extends the clinical evidence, while its deliberately selected family cohort cannot estimate the prevalence of conversion defects in the general population.

Mouse deletion experiments by Zhu and colleagues found that removing Cyp2r1 substantially reduced, but did not abolish, 25(OH)D production. In separate dietary experiments, Roizen and colleagues found lower conversion activity in liver preparations from high-fat-fed female mice. Neither experiment directly measures conversion in human obesity.

Elkhwanky’s 2020 study also found lower CYP2R1 protein in the liver of high-fat-fed mice. Its human component sampled fat from four women before and after gastric bypass. The observed expression change therefore cannot be described as recovery of the human liver.

Hammour’s 2026 human-cell model found reduced conversion after fatty-acid exposure. However, its separate patient liver analysis did not show reduced CYP2R1 expression. Laboratory findings and patient tissue findings therefore remain distinct.

Aatsinki’s experiments linked metabolic regulation to CYP2R1 expression. However, a later diabetic-mouse study by Elkhwanky found lower Cyp2r1 expression alongside increased conversion activity. A fall in one expression measurement therefore does not guarantee a fall in overall production.

Why do these distinctions matter?

The studies ask related questions with different tools. A mutation can alter the protein’s function; a dietary experiment can change several physiological conditions simultaneously; a tissue biopsy measures that tissue; and a blood sample measures what is circulating. Combining them is useful only if those boundaries remain visible.

The key interpretive task is to keep expression, enzyme activity and circulating concentration separate. A coherent explanation becomes stronger when independent measurements agree. A result that disagrees with the proposed explanation must also be retained. The broader relationship between local conversion and biological response is explained in Vitamin D Metabolism at the Cellular Level.

What can reasonably be concluded?

CYP2R1 is an important part of vitamin D conversion, and the experimental evidence shows that this step can respond to metabolic conditions. The human liver consequences of ordinary obesity are less directly established by these particular studies than the mouse findings.

A vitamin D blood result alone cannot reveal how much of its value comes from supply, conversion or other processes. This evidence does not provide a test for personal conversion failure, a treatment recommendation or a reason to transfer experimental animal doses into human use.

Scientific sources

Cheng JB et al. Genetic evidence that the human CYP2R1 enzyme is a key vitamin D 25-hydroxylase. Proceedings of the National Academy of Sciences. 2004;101(20):7711 to 7715. DOI: 10.1073/pnas.0402490101.

Bakhamis S et al. 25-Hydroxylase vitamin D deficiency in 27 Saudi Arabian subjects: a clinical and molecular report on CYP2R1 mutations. Endocrine Connections. 2021;10(7):767 to 775. DOI: 10.1530/EC-21-0102.

Zhu JG et al. CYP2R1 is a major, but not exclusive, contributor to 25-hydroxyvitamin D production in vivo. Proceedings of the National Academy of Sciences. 2013;110(39):15650 to 15655. DOI: 10.1073/pnas.1315006110.

Roizen JD et al. Obesity Decreases Hepatic 25-Hydroxylase Activity Causing Low Serum 25-Hydroxyvitamin D. Journal of Bone and Mineral Research. 2019;34(6):1068 to 1073. DOI: 10.1002/jbmr.3686.

Elkhwanky MS et al. Obesity Represses CYP2R1, the Vitamin D 25-Hydroxylase, in the Liver and Extrahepatic Tissues. JBMR Plus. 2020;4(11):e10397. DOI: 10.1002/jbm4.10397.

Hammour MM et al. Free Fatty acid-induced disruption of hepatic vitamin D metabolism impairs bone homeostasis in an in vitro 3D human liver: bone model. Archives of Toxicology. 2026;100:4151 to 4169. DOI: 10.1007/s00204-026-04431-x.

Aatsinki SM et al. Fasting-Induced Transcription Factors Repress Vitamin D Bioactivation, a Mechanism for Vitamin D Deficiency in Diabetes. Diabetes. 2019;68(5):918 to 931. DOI: 10.2337/db18-1050.

Elkhwanky MS, Kummu O, Hakkola J. Streptozotocin-induced Diabetes Represses Hepatic CYP2R1 Expression but Induces Vitamin D 25-Hydroxylation in Male Mice. Endocrinology. 2022;163(7):bqac060. DOI: 10.1210/endocr/bqac060.

Related reading

Physiology

Vitamin D and Liver Function

Explore how vitamin D and liver function interact through metabolism, insulin signalling, immune balance, and tissue regulation in a physiology-first framework.

Read more →

Original sources

Source

Streptozotocin-induced Diabetes Represses Hepatic CYP2R1 Expression but Induces Vitamin D 25-Hydroxylation in Male Mice

Vitamin D deficiency [ie, low plasma 25-hydroxyvitamin D (25-OH-D)] associates with the prevalence of metabolic diseases including type 1 diabetes; however, the molecular mechanisms are incompletely understood.

Publication details

Elkhwanky MS, Kummu O, Hakkola J. Streptozotocin-induced Diabetes Represses Hepatic CYP2R1 Expression but Induces Vitamin D 25-Hydroxylation in Male Mice. Endocrinology. 2022;163(7):bqac060. DOI: 10.1210/endocr/bqac060.

Read more →